Association of amino-terminal pro-brain natriuretic peptide with metabolic syndrome

Internal Medicine

Volumn 50, Issue 11, 2011, Pages 1143-1147

  Li, Wen Yi ^a   Chiu, Fu Chun ^a   Chien, Yu Fen ^a   Lin, Jou Wei ^a   Hwang, Juey Jen ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Amino terminal pro brain natriuretic peptide; Metabolic cardiovascular syndrome; Propensity score

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; TRIACYLGLYCEROL; URIC ACID;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE;

ADULT; BIOLOGICAL MARKERS; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; FEMALE; HUMANS; INSULIN; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; REGRESSION ANALYSIS; TAIWAN;

EID: 79958043778     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.50.4765     Document Type: Article

References (25)

1. Nakao K, Ogawa Y, Suga S, Imura H. Molecular biology and biochemistry of the natriuretic peptide system. I: Natriuretic peptides. J Hypertens 10: 907-912, 1992.
2. Downie PF, Talwar S, Squire IB, Davies JE, Barnett DB, Ng LL. Assessment of the stability of N-terminal pro-brain natriuretic pep-tide in vitro: implications for assessment of left ventricular dysfunction. Clin Sci (Lond) 97: 255-258, 1999.
3. Ceyhan C, Unal S, Yenisey C, Tekten T, Ceyhan FB. The role of N terminal pro-brain natriuretic peptide in the evaluation of left ventricular diastolic dysfunction: correlation with echocar-diographic indexes in hypertensive patients. Int J Cardiovasc Imaging 24: 253-259, 2008.
4. Berger R, Huelsman M, Strecker K, et al. B-type natriuretic pep-tide predicts sudden death in patients with chronic heart failure. Circulation 105: 2392-2397, 2002.
5. McCord J, Mundy BJ, Hudson MP, et al. Relationship between obesity and B-type natriuretic peptide levels. Arch Intern Med 164: 2247-2252, 2004.
6. Mehra MR, Uber PA, Park MH, et al. Obesity and suppressed B-type natriuretic peptide levels in heart failure. J Am Coll Cardiol 43: 1590-1595, 2004.
7. Wang TJ, Larson MG, Levy D, et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 109: 594-600, 2004.
8. Das SR, Drazner MH, Dries DL, et al. Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study. Circulation 112: 2163-2168, 2005.
9. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288: 2709-2716, 2002.
10. Wilson PW, D'Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 112: 3066-3072, 2005.
11. Wang TJ, Larson MG, Keyes MJ, Levy D, Benjamin EJ, Vasan RS. Association of plasma natriuretic peptide levels with metabolic risk factors in ambulatory individuals. Circulation 115: 1345-1353, 2007.
12. Sezen Y, Bas M, Demirbag R, Yildiz A, Celik H, Aksoy S. N-terminal pro-brain natriuretic peptide in cases with metabolic syndrome and its relationship with components of metabolic syndrome and left ventricular mass index. Clin Biochem 42: 1500-1503, 2009.
13. D'Agostino RB. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 17: 2265-2281, 1998.
14. Chen YS, Lin JW, Yu HY, et al. Cardiopulmonary resuscitation with assisted extracorporeal life-support versus conventional cardiopulmonary resuscitation in adults with in-hospital cardiac arrest: an observational study and propensity analysis. Lancet 372: 554-561, 2008.
15. Olsen MH, Hansen TW, Christensen MK, et al. N-terminal pro brain natriuretic peptide is inversely related to metabolic cardiovascular risk factors and the metabolic syndrome. Hypertension 46: 660-666, 2005.
16. Sarzani R, Dessi-Fulgheri P, Paci VM, Espinosa E, Rappelli A. Expression of natriuretic peptide receptors in human adipose and other tissues. J Endocrinol Invest 19: 581-585, 1996.
17. Sengenes C, Bouloumie A, Hauner H, et al. Involvement of a cGMP-dependent pathway in the natriuretic peptide-mediated hormone-sensitive lipase phosphorylation in human adipocytes. J Biol Chem 278: 48617-48626, 2003.
18. Kalra PR, Tigas S. Regulation of lipolysis: natriuretic peptides and the development of cachexia. Int J Cardiol 85: 125-132, 2002.
19. Kanda H, Kita Y, Okamura T, et al. What factors are associated with high plasma B-type natriuretic peptide levels in a general Japanese population? J Hum Hypertens 19: 165-172, 2005.
20. Hanley AJ, Festa A, D'Agostino RB, et al. Metabolic and inflammation variable clusters and prediction of type 2 diabetes: factor analysis using directly measured insulin sensitivity. Diabetes 53: 1773-1781, 2004.
21. Hwang JJ, Li HY, Shieh GJ, Chien YF, Hua CH, Lin JW. Illustrating the roles of C-reactive protein in the development of the metabolic syndrome in women--a cross-racial validation. Nutr Metab Cardiovasc Dis 18: 671-677, 2008.
22. Leyva F, Anker SD, Godsland IF, et al. Uric acid in chronic heart failure: a marker of chronic inflammation. Eur Heart J 19: 1814-1822, 1998.
23. Bolger AP, Anker SD. Tumour necrosis factor in chronic heart failure: a peripheral view on pathogenesis, clinical manifestations and therapeutic implications. Drugs 60: 1245-1257, 2000.
24. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425: 516-521, 2003.
25. Lin LY, Kuo HK, Li HY, Hwang JJ, Lin JW. Confirming a biological pathway in the metabolic syndrome--insight from the NHANES 1999-2002. Obesity (Silver Spring) 16: 2676-2681, 2008.